**Vitamin D: Link between Osteoporosis, Obesity, and Diabetes?**

Flávia Galvão Cândido * and Josefina Bressan

Laboratory of Body Composition and Energy Metabolism, Departamento de Nutrição e Saúde-CCB II, Universidade Federal de Viçosa, Avenida PH Rolfs, s/n, Viçosa, MG 36570-900, Brazil; E-Mail: ppgcnut@ufv.br

* Author to whom correspondence should be addressed; E-Mail: flaviagcandido@hotmail.com; Tel.: +55-31-3899-3388; Fax: +55-31-3899-2541.

Received: 24 February 2014; in revised form: 24 March 2014 / Accepted: 4 April 2014 / Published: 17 April 2014

**Abstract:** Vitamin D (1,25(OH)2D3) is a steroid hormone that has a range of physiological functions in skeletal and nonskeletal tissues, and can contribute to prevent and/or treat osteoporosis, obesity, and Type 2 diabetes mellitus (T2DM). In bone metabolism, vitamin D increases the plasma levels of calcium and phosphorus, regulates osteoblast and osteoclast activity, and combats PTH hypersecretion, promoting bone formation and preventing/treating osteoporosis. This evidence is supported by most clinical studies, especially those that have included calcium and assessed the effects of vitamin D doses (≥800 IU/day) on bone mineral density. However, annual megadoses should be avoided as they impair bone health. Recent findings suggest that low serum vitamin D is the consequence (not the cause) of obesity and the results from randomized double-blind clinical trials are still scarce and inconclusive to establish the relationship between vitamin D, obesity, and T2DM. Nevertheless, there is evidence that vitamin D inhibits fat accumulation, increases insulin synthesis and preserves pancreatic islet cells, decreases insulin resistance and reduces hunger, favoring obesity and T2DM control. To date, there is not enough scientific evidence to support the use of vitamin D as a pathway to prevent and/or treat obesity and T2DM.

**Keywords:** vitamin D; osteoporosis; obesity; diabetes mellitus; PTH; bone mineral density; falls; fractures; osteoblasts; osteoclasts
1. Introduction

Vitamin D is a topic of great interest for the scientific community as well as for the layman. The commonly-known function of vitamin D has been associated with skeletal tissue, in which vitamin D influences mineralization, bone turnover rate, and occurrence of fractures, contributing to the prevention and treatment of osteoporosis [1]. Nevertheless, the recent discovery of ample distribution of vitamin D receptors (VDR) in non-skeletal tissues dramatically increased the interest in this vitamin as a therapeutic modality for the prevention of chronic diseases, such as obesity and Type 2 diabetes mellitus (T2DM) [2]. During the two-year period of 2012 and 2013, over 350 articles were published in high impact journals containing vitamin D and obesity/diabetes in the title. Additionally, factors derived from skeletal tissue, such as the osteocalin and the osteopontin, can affect body weight and glycemia [3,4], suggesting an indirect role of vitamin D in these parameters.

Despite the relevance of the topic and the evidence of the association between vitamin D, obesity, and T2DM, current recommendations of this vitamin only considered the effects of vitamin D on skeletal tissue [5–7]. In the present review, we critically investigated the effects of vitamin D on osteoporosis, obesity, and T2DM, with special focus on randomized controlled trials conducted on adults and the elderly. We intended to evaluate vitamin D as a link between skeletal and chronic non-skeletal disorders and not to exhaustively revisit the topic. The interrelation between osteoporosis, obesity, and T2DM and their mechanisms are also considered, regarding the effects of vitamin D on these relationships.

2. Methodology

Medline/PubMed, Science Direct, Scientific Electronic Library Online (SCIELO), and Latin American and Caribbean Health Sciences Literature-LILACS electronic databases were searched to identify studies published within the last 10 years regarding the effects of vitamin D on osteoporosis, obesity, and diabetes. For data searches, the following main terms were used alone or in association: vitamin D, vitamin D receptor, parathormone (PTH), osteoporosis, bone health, obesity, adiposity, weight, insulin resistance, diabetes, metabolic syndrome, and β-cell function. Review and original articles were selected according to their titles and abstracts. Each selected manuscript was then studied critically.

3. Vitamin D

Vitamin D, in its metabolically active form, 1,25(OH)₂D₃, is a steroid hormone obtained after hepatic (C-25 position), and not exclusively, kidney (C-1) hydroxylations. Its precursors can be acquired from the diet as well as sun exposure; the latter being due to non-enzymatic reactions by exposing the skin to ultraviolet radiation [8]. Sun exposure can produce more vitamin D than the diet, even when nutritional supplements of the recommended concentrations are included [3]. However, the large number of factors affecting the synthesis and/or bioavailability of vitamin D and the fact that ultraviolet radiation is classified as a Group 1 carcinogen by the International Agency for Research on Cancer, increase the importance of diet in maintaining adequate levels of this vitamin [9].

Decreased sun exposure related to latitude, seasonality, time of day, atmospheric components, clothing, and sunscreen use, compromise vitamin D synthesis in individuals [10]. The pigmentation of the skin also affects vitamin D synthesis capacity, since melanin effectively absorbs electromagnetic
radiation and competes with the vitamin’s precursors [11]. The bioavailability of vitamin D depends on its intestinal absorption capacity, liver health of the individuals, and their fat storage. Adipose tissue easily absorbs vitamin D ingested or produced by chemical affinity. Some authors suggest that the accumulation of vitamin D in adipose tissue is important for its subsequent release during times of reduced production (for example, during winter when the fat storage decreases) [12]. All of these factors should be taken into consideration upon evaluating studies involving the role of vitamin D.

The 25(OH)D₃ is considered the best indicator of nutritional and functional status of vitamin D, because it is present in higher concentrations in the blood, has a long half-life (15 to 20 days), and there are many available techniques for its evaluation [13]. Although 1,25(OH)₂D₃ corresponds to the active form of the vitamin, it circulates in the bloodstream in concentrations 1000 times lower to that of 25(OH)D₃ and its half-life is only 4 to 6 h [14]. In addition, levels of 25(OH)D₃ fail as indicators of 1,25(OH)₂D₃ status just in patients with calcitriol synthesis abnormalities (e.g., sarcoidosis) or with rare phosphate or vitamin D metabolism disorders [2,13]. The most accepted classification of vitamin D status considers deficient those individuals who have 25(OH)D₃ serum levels below 20 ng/mL (50 nmol/L), insufficient in those with levels between 21 to 29 ng/mL (52.5 to 72.5 nmol/L), and sufficient with levels of 30 to 44 ng/mL (75 to 110 nmol/L) [2,15,16]. Although there are efforts to raise these normality values, Bischoff-Ferrari et al. [16] stressed that there is currently no data to support that levels above 50 ng/mL result in more additional benefits than the 30 to 44 ng/mL range. The benchmark, 100 ng/mL (250 nmol/L), should be considered as a safety limit, but not as an upper limit to reach in clinical practice. Although this level is considered safe, it is not the desirable level for optimal health results [15].

The active vitamin D is capable of binding to an intracellular transcription receptor called vitamin D receptor (VDR). The identification and cloning of VDR occurred only in 1987 and, since then, new tissue-specific functions of vitamin D have been discovered. Currently, it is known that the VDR is widely distributed among tissues and that the absence of the receptor is the exception, not the rule [5]. The majority, if not all of vitamin D’s functions, are mediated by the VDR acting in the regulation of gene expression in specific DNA regions. Vitamin D binds to its nuclear receptor (nVDR) with high affinity and specificity; the receptor works in partnership with other transcription factors, such as the retinoid X receptor (RXR). The group formed by vitamin D, RXR, and VDR can recognize the vitamin D responsive elements (VDREs) of genes regulated by vitamin D [8]. Some immediate vitamin D action may occur by other less-known pathways, which involves the participation of the VDR bound to the plasma membrane (mVDR) and not the nVDR (Figure 1) [5].

One of the most common disorders related to low vitamin D levels is secondary hyperparathyroidism. Parathyroid cells that have VDR and vitamin D deficiency, with or without low expression of VDR in these cells, causes an increase in circulating levels of the parathyroid hormone (PTH), which is responsible for a number of metabolic alterations in skeletal and non-skeletal tissues [17]. Therefore, vitamin D mediates metabolic alterations resulting from high PTH levels.
Figure 1. Vitamin D biosynthesis and action. Precursors of vitamin D are incorporated by foods, supplements, or synthesized by skin after UV-radiation and heat. These precursors are stocked in adipose tissue or carried to liver and kidneys for hydroxylation by the enzymes P450C25 and P450C1 hydroxylases, respectively. The metabolic active form of vitamin D (1,25(OH)2D3) is transported through the bloodstream by vitamin-D-binding protein (DBP). In target cells, 1,25(OH)2D3 follows two distinct pathways. Target cells that have nuclear vitamin D receptors (nVDR) will trigger a better understood pathway involving: activation of nVDR by 1,25(OH)2D3; connection with other transcription factors, such as retinoid X receptors (RXR); formation of a complex capable of recognizing response elements of vitamin D (VDRE); and induction or repression of specific genes. On the other hand, target cells that have membrane vitamin D receptors (mVDR) will trigger a less understood pathway, maybe involving the activation of mVDR by 1,25(OH)2D3 and the rapid opening of a G-protein-coupled membrane-bound calcium channel. These mechanisms modulate the synthesis of parathormone (PTH) and, together with the diminished PTH levels, act in the metabolism of skeletal and non-skeletal tissues. Adapted with permission from Nature Publishing Group: Nature Reviews Cancer [18] copyright 2003.

4. Vitamin D and Osteoporosis

4.1. Mechanisms of Action

The main role of vitamin D in bone metabolism is to increase the plasma levels of calcium and phosphorus, essential for mineralization. The increase in circulating levels of calcium is also necessary
for the proper functioning of nerve transmission, neuromuscular junctions and hormone secretion, in particular PTH [1]. All these mechanisms increase bone mineral density and reduce the risk of falling by increasing muscle tone, which contributes to reducing osteoporosis and its consequences.

Vitamin D in its active form (1,25(OH)₂D₃) is able to increase circulating levels of calcium and phosphorus to normal levels through three pathways. The first pathway, and most well established, is by stimulating the absorption of calcium and phosphate in the intestine, particularly in the duodenum and jejunum. This occurs due to the opening of calcium channels and by the formation of calcium-binding protein, independent of PTH [1,4]. Vitamin D is able to increase the absorption rate of calcium in the intestine, which is usually 10% to 15% during passive transport, 30% to 40% under normal conditions, reaching up to 60% to 80% during pregnancy and lactation [14,19]. The second pathway, dependent on PTH, occurs through mobilization of calcium and phosphorus from bone. In this process, there is increased expression of the receptor activator for nuclear factor κB ligand (RANKL) protein in the osteoblasts, capable of binding to the pre-osteoclast RANK and promoting osteoclastogenesis and bone resorption [14,20,21]. Vitamin D in the osteoblasts is also capable of highly stimulating the synthesis of osteocalcin and moderately osteopontin [22]; two structural proteins present in the organic matrix related to bone remodeling that have a hormonal function in peripheral tissues [6,7]. In osteoclasts, vitamin D exerts a direct function by stimulating osteoclastogenesis [23], although the indirect action via osteoblasts is the most recognised. The third pathway is also dependent on the PTH and involves the increase in renal retention of calcium due to increased tubular reabsorption or a decrease of filtered load [19]. The renal function of vitamin D is well known and many proteins involved in the process have been identified, although the molecular mechanisms are not well understood [1].

Mineralization is a passive process, but it only occurs when calcium and vitamin D are available in sufficient quantities. In vitamin D deficiency, there is a decrease in circulating levels of calcium and increased PTH levels. PTH acts by increasing P450C1 hydroxylase activity in the kidney, which consequently increases vitamin D serum levels, and is a potent agent in bone resorption. In this new phase, the circulating levels of vitamin D and calcium are normal, but the bone reserves become compromised. If vitamin D deficiency occurs for a prolonged period, substrates for synthesis of the active form of the vitamin may be reduced and the resulting bone loss can lead to osteoporosis [4,14]. In contrast, normal vitamin D levels promote adequate calcium levels in the bloodstream. The parathyroid gland cells are sensitive to these two elements by having VDR and calcium-sensing receptors, which act by combating PTH hypersecretion and the resulting bone resorption [17,24]. It is worth remembering that bone tissue is dynamic and that the resorption process is also part of the formation process. Bone loss occurs only when there is an imbalance, with increased resorption in relation to formation [25]. Vitamin D, although it may act on bone resorption, promotes bone formation over the long term [26], in part by increasing intestinal absorption of calcium and combating the hypersecretion of the potent bone resorption agent, PTH (Figure 2).
Figure 2. A simplified model of potential mechanisms in the modulation of osteoporosis, obesity, and diabetes through reduction in vitamin D. Red lines: inhibition pathways. Dotted lines: not well established mechanisms. PHT: parathormone; Ca++: calcium; p: phosphorus.
4.2. Scientific Evidences

The state of vitamin D is related to bone mineral density (BMD) in both deficient as well as insufficient individuals. Cross-sectional studies have demonstrated a positive relationship between serum levels of 25(OH)D₃ and BMD [27–29] with varying limits of 25(OH)D₃, from which the BMD reaches a plateau. These limits vary from 20 ng/mL (50 nmol/L) [28] to 36 ng/mL (90 nmol/L) [27], depending on the target population and the geographical region where BMD was measured. Similarly, a decrease was observed in the incidence of fractures in individuals with 25(OH)D₃ serum levels greater than 12 ng/mL (30 nmol/L) [30] and the average mean 25(OH)D₃ levels were higher in subjects with less severe fractures compared to those with severe fractures [31]. It is noteworthy that these reference values seem to be the same at which PTH level stabilization occurs [32], i.e., 25(OH)D₃ levels sufficient to establish the best relationship with BMD and with fracture risks are also responsible for the lower levels of PTH, suggesting an important role of PTH in the process.

The effect of vitamin D supplementation, concomitant or not with calcium, has been evaluated in various controlled clinical trials (Table 1). As primary outcomes, the studies had BMD and/or the incidence of falls/fractures, and the fractures and BMD were evaluated in different anatomical regions. Most of them involved postmenopausal women and/or those with high risk of developing fractures. The daily doses of calcium adopted in the studies ranged from 500 to 1200 mg/day. Vitamin D, in turn, had wide variation in dosage, form and frequency of administration.

4.2.1. Vitamin D and BMD

Among the studies that evaluated the effects of vitamin D on BMD [26,33–45], only four [37,39–41] showed no significant effect of supplementation, validating the use of vitamin D as a way to prevent and/or treat bone loss. These four studies [37,39–41], however, included higher doses of vitamin D (2857 to 7143 IU/day) [37,39,40], younger men and women with reduced risks of having bone formation deficiency [37,40], less time duration [39,41], and/or small populations [39–41]. All these factors may have contributed to the lack of significant results in these studies.

The use of moderate doses of vitamin D (800 IU/day) appears to be more effective in the reduction of bone turnover and increased BMD compared to high doses (6500 IU/day) [42]. However, in obese subjects, the 7000 IU/day dose of this vitamin was effective in reducing bone turnover and increasing BMD [45]. It is possible that the uptake of vitamin D from adipose tissue is responsible for the increase in the action threshold of vitamin D in bone health in overweight subjects. Additionally, vitamin D supplementation appears to have different effects on individuals with different VDR polymorphisms. Black women with genotype FF for the Fokl allelic region had higher bone loss, but were more responsive to vitamin D supplementation [43]. This information indicates that the population characteristics influence the results of vitamin D supplementation on BMD. It is noteworthy that the best anatomical region for BMD monitoring is the posteroanterior spine region, having greater precision and being more responsive to treatment [46]. The use of other anatomical regions may not be as sensitive and may impair the analysis of the results.
Table 1. Effects of vitamin D supplementation with or without calcium on serum vitamin D and bone status.

| Study          | n (gender) y, duration | Vit D suppl. | Ca++ suppl. | Design                | Final serum 25(OH)D$_3$ (nmol/L) | Bone outcomes                                                                 |
|----------------|------------------------|--------------|--------------|-----------------------|----------------------------------|--------------------------------------------------------------------------------|
| Trivedi et al. [47] | 2686 (649F, 2037M) 65–85 y, 5 years | 100,000 IU/4 months | -            | Oral vit D            | - Vit D: 74.3                    | RR (treatment vs. control) of 0.78 (95% CI 0.61–0.99) for any first fracture, 0.67 (0.48–0.93) for first hip, wrist or forearm, or vertebral fracture |
| Harwood et al. [33] | 150 (F) 67–92 y, One year | 800 IU/day; 300,000/year | 1000 mg/day | - Single injection    | Treatment groups: 40.0–50.0      | † BMD (control vs. treatments): 1.1%–3.3% neck of femur; 2.5%–4.6% trochanter; 2.1%–4.6% total hip. |
| Larsen et al. [48]  | 9605 (5771F, 3834M) 66–103 y, 3 years | 400 IU/day | 1000 mg/day | Oral Ca++               | - Environmental                  | RR of fall: 0.48 (95% CI 0.26–0.90)                                       |
| Grant et al. [49]  | 5292 (4481F, 811M) 70 y or older, 2–5.2 years | 800 IU/day | 1000 mg/day | Oral Ca++               | -                                | RR (treatment vit D + Ca++ vs. control) of 0.84 (95% CI 0.72–0.98) for fracture incidence |
| Porthouse et al. [50] | 3314 (F) 70 y or older, 1.5–3.5 years | 800 IU/day | 1000 mg/day | Oral Vit D + oral Ca++ | -                                | In subjects who took at least half the prescribed capsules: Incident rate ratio of 0.67 (95% CI 0.48–0.82) for falls; OR of 0.70 (95% CI 0.50–0.99) for any falling |
| Flicker et al. [51] | 625 (593F, 32M) 2 years | 10,000 IU/week (1); 1000 IU/day (2) | 600 mg/day | Oral vit D (start in 1 and finish in 2) + oral Ca++ | -                                | In subjects who took at least half the prescribed capsules: Incident rate ratio of 0.67 (95% CI 0.48–0.82) for falls; OR of 0.70 (95% CI 0.50–0.99) for any falling |
| Jackson et al. [34] | 36,282 (F) 50–79 y, 7 years | 400 IU/day | 1000 mg/day | Oral vit D + oral Ca++ | -                                | † BMD (treatment vs. control): 1.06% (p < 0.01); HR for hip, clinical spine, or total fractures: NS |
| Lyons et al. [52]  | 3440 (2624F, 816M) 62–107 y, 3 years | 100,000 IU/4 months | -            | Oral vit D            | - Vit D: 80.1                    | Incidence of fractures: NS                                               |

Note: RR = relative risk; CI = confidence interval; BMD = bone mineral density; NS = not significant; OR = odds ratio; VIT = vitamin; Ca++ = calcium; IU = international units; mg/day = milligrams per day; IU/week = international units per week; % = percent; mol/L = molar per liter; ppm = parts per million; g = gram; mg = milligram; nmol/L = nanomol per liter; ppm = parts per million.
| Study                          | n (gender) y, duration | Vit D suppl. | Ca++ suppl. | Design | Final serum 25(OH)D₃ (nmol/L) | Bone outcomes                                                                                                                                 |
|-------------------------------|------------------------|--------------|-------------|--------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Smith et al. [53]             | (5086F, 4354M) 75 y or older, 3 years | 300,000 IU/year | -           | Intramuscular vit D          | 106.4 ± 29.0                                                                  | - HR (treatment vs. control) of 1.49 for hip fracture (95% CI 1.02–2.18)  
- HR for any first fracture or for wrist: NS  
- Ca++ and Vit D + Ca++ groups: maintenance of hip BMD vs. control group at year 1  
- Only Vit D + Ca++ group keeps this result at year 3 (2.8% ± 1.1%, $p = 0.01$) and 5 (2.2% ± 1.1%, $p = 0.05$)  
- More pronounced results in individuals with less 25(OH)D₃ at baseline.                                                      |
| Zhu et al. [26]               | 120 (F) 70–80 y, 5 years | 1000 IU/day | 1200 mg/day | Oral D + oral Ca++           | 106.4 ± 29.0                                                                  | - Only Vit D + Ca++ group keeps this result at year 3 (2.8% ± 1.1%, $p = 0.01$) and 5 (2.2% ± 1.1%, $p = 0.05$)  
- More pronounced results in individuals with less 25(OH)D₃ at baseline.                                                      |
| Pfeifer et al. [54]           | 242 (191F, 51M) 70 y or older, One year | 800 IU/day | 1000 mg/day | Oral Ca++                      | 57.0                                                                          | - RR (treatment vs. control) of 0.73 for first falls (95% CI 0.54–0.96)  
- BMD change differences at the lumbar spine, femoral neck, trochanter, and total proximal femur: NS  
- Changes (final–initial; control vs. treatment): BMD in arms: −0.047; 0.033, $p < 0.001$  
BMD in total spine: 0.049; 0.118, $p = 0.001$;  
BMD in total body: −0.020; 0.003, $p < 0.001$                                                      |
| Kärkkäinen et al. [35]        | 593 (F) 66–71 y, 3 years | 800 IU/day | 1000 mg/day | Oral D + oral Ca++           | 74.6 ± 21.9                                                                  | - BMD change differences at the lumbar spine, femoral neck, trochanter, and total proximal femur: NS  
- RR (treatment vs. control) of 1.15 for fell (95% CI 1.02–1.30)  
- RR (treatment vs. control) for fracture was 1.26 (1.00–1.59)  
- A temporal pattern was observed for falls (RR of 1.31 in the first 3 months and 1.13 during the following 9 months) |
| Moschonis et al. [36]         | 66 (F) 55–65 y, 2.5 years | 300 IU/day (1) | 1200 mg/day for 1 y and oral vit D(2)+oral Ca++ for 1.5 y | - oral vit D(1) + oral Ca++ | Controls: 55.9 ± 21.8 | - BMD at the lumbar spine and the hip: NS  
- Changes (final–initial; control vs. treatment): BMD in arms: −0.047; 0.033, $p < 0.001$  
BMD in total spine: 0.049; 0.118, $p = 0.001$;  
BMD in total body: −0.020; 0.003, $p < 0.001$                                                      |
| Jorde et al. [37]             | (265F, 156M) 21–70 y, One year | 40,000 IU/week (1) | 500 mg/day | Oral D(1) + oral Ca++; 141.0 (1) | - BMD at the lumbar spine and the hip: NS  
- Changes (final–initial; control vs. treatment): BMD in arms: −0.047; 0.033, $p < 0.001$  
BMD in total spine: 0.049; 0.118, $p = 0.001$;  
BMD in total body: −0.020; 0.003, $p < 0.001$                                                      |
| Sanders et al. [55]           | 2256 (F) 70 y or older, 3–5 years | 500,000 IU/year | - | Oral vit D                      | Vit D: 74.0                                                                   | - RR (treatment vs. control) of 1.15 for fell (95% CI 1.02–1.30)  
- RR (treatment vs. control) for fracture was 1.26 (1.00–1.59)  
- A temporal pattern was observed for falls (RR of 1.31 in the first 3 months and 1.13 during the following 9 months) |
| Salovaara et al. [56]         | 3432 (F) 65–71 y, 3 years | 800 IU/day | 1000 mg/day | Oral D + oral Ca++           | 74.6                                                                          | - HR for any first fracture, nonvertebral, distal forearm or upper extremity fractures: NS  
- Changes (final–initial; control vs. treatment): BMD in arms: −0.047; 0.033, $p < 0.001$  
BMD in total spine: 0.049; 0.118, $p = 0.001$;  
BMD in total body: −0.020; 0.003, $p < 0.001$                                                      |
Table 1. Cont.

| Study                  | n (gender) y, duration | Vit D suppl. | Ca++ suppl. | Design                                      | Final serum 25(OH)D$_3$ (nmol/L) | Bone outcomes                                                                 |
|------------------------|------------------------|--------------|-------------|---------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Islam et al. [38]      | 200 (F) 16–36 y, One year | 400 IU/day   | 600 mg/day  | - Oral vit D(VD)                            | -VD: 69.2                         | - Changes (final–initial; control vs. treatments) BMD in femoral neck: -0.010 (C); 0.012 (VD); 0.013 (VDC); 0.017 (VDCM); p < 0.001; BMD in trochanter: −0.017 (C); 0.002 (VD); 0.001 (VDC); 0.010 (VDCM); p < 0.001 |
| Rastelli et al. [39]   | 60 (F) Mean values of 60 and 63 y 6 months | 400 IU/day + 50,000 IU/weekly and then monthly | 1000 mg/day Ca++ (control) | - Oral vit D + oral Ca++                       | -Vd + Ca++: 74.3                  | - BMD at the femoral neck decreased in the placebo and did not change in the treatment group (p = 0.06) |
| Steffensen et al. [40] | 71 (F, M) 18–50 y, 2 years | 20,000 IU/week | 500 mg/day  | - Oral vit D + oral Ca++                       | -Vd + Ca++: 123.2                 | - BMD did not differ between groups at total hip, lumbar spine, and ultra-distal radius |
| Verschueren et al. [41] | 113 (F) 70 y or older, 6 months | 880 IU/day (1) / 1600 IU/day (2) | 1000 mg/day | - Oral vit D(1) + oral Ca++ ** - Oral vit D(2) + oral Ca++ ** | -Vd(1) + Ca++: 77.6 -Vd(2) + Ca++: 84.6 | - High dose of vitamin D did result in higher serum vitamin D levels but did not result in hip BMD improvements |
| Grimnes et al. [42]    | 297 (F) 50–80 y, One year | 6500 IU/day (1) / 800 IU/day (2) | 1000 mg/day | - Oral vit D(1) + oral Ca++ - Oral vit D(2) + oral Ca++ | -Vd(1) + Ca++: 185.4 -Vd(2) + Ca++: 89.2 | - BMD was unchanged or slightly improved with no significant differences between the groups - Vit D(2) may be more efficient in reducing bone turnover - Changes in BMD were not different between placebo- and vitamin D-treated black women at lumbar spine, total hip, and femoral neck - Femoral neck BMD was only responsive to vitamin D in VDR Fok1 polymorphism FF subjects, not Ff/ff subjects |
| Nieves et al. [43]     | 103 (F) Mean values of 62.3 and 61.2 y, 2 years | 1000 IU/day | 1000 mg/day | - Oral vit D + oral Ca++                       | -Vd + Ca++: ~55.0                 | - BMD loss at the hip was less for the 1000 IU vitamin D group (0.05%) compared with the 400 IU vitamin D or placebo groups (0.57% and 0.60%, respectively) (p < 0.05) - BMD at the ultradistal forearm significantly increased in the treatment group compared with a decrease in the placebo group - Changes in BMD between groups do not differ at lumbar spine, hip or whole body |
| Macdonald et al. [44]  | 305 (F) 60–70 y, One year | 400 IU/day (1) / 1000 IU/day (2) | - | - Oral vit D(1) - Oral vit D(2) | -Vd(1): 76.4 -Vd(2): 65.4 | |
| Wamberg et al. [45]    | 52 (F, M) 18–50 y, 6 months | 7000 IU/day | - | - Oral vit D | -Vd: 110.0 | |

BMD: bone mineral density; Y: years; Vit D: vitamin D; Ca: calcium; CI: confidence interval; HR: hazard ratio; RR: relative risk; OR: odds ratio; NS: nonsignificant; * After 2 years; ** With or without Whole-Body Vibration Training Program.
4.2.2. Vitamin D and Falls/Fractures

Among the studies that evaluated the effects of vitamin D on the risk of falls and/or fractures [33,34,47–56], positive effects were observed in some [33,47,48,51,54], but not all [34,49,50,52,53,55,56], studies and in two of them [53,55] supplementation was harmful. The improvement in the evaluated parameters showed up to a 52% decrease in the risk of fall [33] and a 33% decrease in the risk of fractures in the hip, wrist/forearm, and vertebrae [47].

The lack of significant results in some studies may have various causes. It is possible that the falls/fractures are less sensitive parameters than BMD to assess the effects of vitamin D supplementation, since they occur at a more advanced stage of bone depletion, and thus some studies might not have been able to demonstrate the effect of the vitamin on these parameters. Some studies showed less than 60% compatibility in the intake of supplements, vitamin D, and calcium [49,50] and that the follow-up treatment is essential to verify the success of any intervention. Furthermore, the 400 IU/day dose of vitamin D is insufficient to raise and maintain serum levels within the normal range and to decrease the risk of hip and other nonvertebral fractures [44,57]. Bischoff-Ferrari et al. [58] suggest that a minimum daily dose of 800 IU is needed to affect the incidence of fractures.

Although vitamin D has a protective role in the incidence of falls/fractures, proven by most studies, the deleterious effect of high dosages should be noted. Sanders et al. [55] showed that annual mega doses of 500,000 IU of vitamin D increase the risk of falls and fractures by 15% and 26%, respectively. The authors speculate that high serum levels of vitamin D or its metabolites, resulting from the large annual dose, and subsequent decrease in these levels, or both, may be the cause of harm. Smith et al. [53] also found a deleterious effect of a 300,000 IU annual dose of vitamin D on the incidence of hip fracture (49% increase). It is noteworthy, however, that both aforementioned studies [53,55] did not ally the consumption of calcium with the vitamin D supplementation. The study conducted by Harwood et al. [33] employed the same dose and dosing interval as that of Smith et al. [53], but included 1000 mg/d of calcium and obtained positive results. Another question concerns the dosing interval. Trivedi et al. [47] adopted the same dosage as Smith et al. [53], but in a rationed manner (100,000 IU every four months) and obtained positive results with vitamin D, even when not combined with calcium. These studies indicate that the addition of calcium and the adoption of shorter intervals between administrations can be essential to the success of vitamin D supplementation in the prevention and/or control of osteoporosis.

5. Vitamin D, Obesity, and T2DM

5.1. Mechanisms of Action

The role of vitamin D in the pathophysiology of obesity and T2DM is a subject of debate in the scientific community. Although many observational studies have demonstrated a negative association between indicators of obesity and/or T2DM and serum levels of vitamin D, the cause and effect relationship of these variables is not well established [59].

Some mechanisms are proposed to explain how vitamin D deficiency promotes obesity and T2DM. The VDRs are sensitive to 1,25(OH)2D3 and widely expressed in adipose, pancreatic, and possibly muscle cells [60,61]. Adipocytes and β-pancreatic cells also possess the capacity to activate vitamin D
by having the enzyme 25-hydroxyvitamin D 1-α-hydroxylase [62,63]. In adipocytes, there is evidence that vitamin D inhibits the active form of adipogenic transcription factors and fat accumulation during the differentiation phase [63]. In the β-pancreatic cells, vitamin D appears to modulate insulin synthesis via the nVDR, since there are VDREs in the insulin promoter genes [64]. Vitamin D may also promote morphological improvement in pancreatic islet cells, decrease apoptosis, and have nongenomic effects mediated by mVDR [65]. In skeletal muscle, vitamin D can decrease insulin resistance and increase glucose uptake [66]. The increased secretion and/or insulin action is related to decreased hunger and food intake, helping to reduce obesity [67]. Additionally, mice with VDR deficiency in adipocytes presented a lean phenotype [68]; 1,25(OH)2D3 directly activates the human insulin receptor gene [69], the peroxisome proliferator-activated receptor delta (PPAR-δ) [70], besides stimulating the insulin receptor expression and increasing the transport of in vitro insulin-mediated glucose [71]. Thus, vitamin D deficiency can cause the accumulation of body fat and compromise normal metabolic functioning, favoring obesity and T2DM.

Adipose tissue, in turn, can act by lowering serum levels of vitamin D. This fat soluble vitamin can be stored in adipose tissue and further questions still remain about how its reentry into the bloodstream occurs [72]. Thus, low levels of serum vitamin D would be a result of obesity and not its cause. This hypothesis gained prominence recently with the publication of a study that assessed the causality and direction of the relationship between BMI and serum 25(OH)D3 [73]. After gathering and evaluating consistent data from 21 cohorts (over 42,000 participants), the authors concluded that elevated BMI levels are the cause of the decrease in 25(OH)D3 in the bloodstream. Regardless of the source, however, decreased levels of serum vitamin D can reduce circulating calcium and induce secondary hyperparathyroidism [17]. The increase in PTH may induce weight gain, obesity, and T2DM. The PTH chronically increases intracellular levels of ionic calcium in adipocytes, which may act reciprocally on increased expression of fatty acid synthase (FAS)—a key regulatory enzyme in the deposition of lipids—and on decreased lipolysis. Decreased thermogenesis and lipid oxidation through the down-regulation of uncoupling proteins is also suggested [67].

Vitamin D can also act indirectly on the control of obesity and diabetes. The high increase in osteocalcin synthesis by osteoblasts appears to regulate body fat and improve glucose tolerance by stimulating insulin synthesis in the pancreas and adiponectin in adipocytes [74]. On the other hand, increased osteopontin, even if moderate, stimulates the growth of adipose tissue and the development of chronic low-grade inflammation associated with obesity and insulin resistance [75,76]. Despite conflicting mechanisms, the overall modulation of the osteocalcins by vitamin D seems to favor the control of obesity and its comorbidities [77]. Other targets of vitamin D action are immune system cells. There, this vitamin can reduce the hypersecretion of chemokines and cytokines in monocytes [78], and control functions, maturation and/or growth of dendritic cells [79], T [80] and B cells [81]. A detailed review on the subject was published by Baeke et al. [82], but, in general, published studies indicate that 1,25(OH)2D3 acts on various cells of the immune system to generate a more tolerant and anti-inflammatory response profile (Figure 2).
5.2. Scientific Evidences

Many observational studies have shown a consistent and strong negative association between obesity and/or T2DM indicators and vitamin D serum levels [83–96]. Nevertheless, some observational studies that have evaluated the effects of vitamin D on insulin secretion and/or action have shown mixed results, since the effects disappeared after adjustment for adiposity [97–100]. These results suggest that adiposity, and not the vitamin D serum levels, is what influences insulin.

Possible explanations for the lack of unanimity on the relationships between obesity, insulin action and secretion, and serum levels of vitamin D were described by Lamendola et al. [59]. According to the authors, the estimation (not direct measure) of the insulin-mediated glucose availability, the absence of methods for adjustments in large populational studies, and the possibility that low vitamin D levels are the consequence and not the cause of obesity are the main reasons for the divergence between some studies. However, even if obesity promotes the decline of circulating vitamin D levels, excess weight is a common condition in diabetic patients and this does not exclude a possible interference of vitamin D on insulin secretion and action. In other words, vitamin D supplementation may be effective in preventing or controlling T2DM even when low levels of this vitamin are due to adiposity, and this should be evaluated in intervention studies.

Randomized double-blind clinical trials that offer the best evidence on the cause and effect relationships between variables are still scarce and inconclusive to establish the relationship between vitamin D, obesity and/or T2DM (Table 2). There is a wide variation in the doses (from 200 to the equivalent of 24,000 IU/day) and intervention time (6 weeks to 7 years). The studies that have associated vitamin D and calcium used doses of 500 to 1500 mg/day of the mineral.

The effects of vitamin D, without caloric restriction, on weight/adiposity control were observed in two recent studies [101,102]. In the first study [101], adult men and women who received 300 IU of vitamin D daily in conjunction with 1050 mg of calcium had a 160% increase in visceral fat reduction compared to the placebo group. In the second [102], a negative association between changes in vitamin D serum levels and BMI was observed in elderly subjects after the daily intake of 600 IU of vitamin D. These results indicate that vitamin D, even at doses within the recommended ranges and when not associated with calcium or restrictive diet, can help reduce body fat and that individuals with lower baseline levels of the vitamin may be most benefited. Another study [103], however, showed no improvement in the success of the intervention with the addition of vitamin D in relation to the group that received only calcium. In this study [103], postmenopausal women gained less truncal fat and more lean mass remained in the same region when they received 1100 IU vitamin D combined with 1400 to 1500 mg calcium or just the same dose of calcium daily for four years. It should be mentioned that the calcium doses adopted were higher than current recommendations and that, at recommended doses, the effects of the increased intake of vitamin D may be more easily detected.

When coupled with nutritional interventions aimed at weight loss, vitamin D appears to improve treatment response in relation to lipid profile [104] and serum PTH levels, triglycerides and TNF-α inflammation marker [105], but not to the adiposity markers [104,105]. A good lipid profile and inflammatory status reduction are essential for healthy weight loss, since the occurrence of transient dyslipidemia during energy restriction diets is common, and that, along with inflammation resulting from excess weight, may increase the risk of developing cardiovascular disease.
| Study          | n (gender) y, duration | Vit D suppl. | Ca++ suppl. | Design                                      | Outcomes                                                                                                                                                                                                 |
|---------------|------------------------|--------------|--------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Major et al. [104] | 63 (F) ~42.6 y, 15 weeks | 200 IU/day   | 600 mg/day   | Double-blind RCT                           | Greater decreases (treatment vs. control) in total cholesterol/LDL, LDL/HDL and LDL                                                                                                                          |
| Pittas et al. [84] | 314 (F, M) 65 y or older, 3 years | 700 IU/day   | 500 mg/day   | Double-blind RCT                           | The differences were independent of changes in fat mass and in WC                                                                                                                                     |
| de Boer et al. [85] | 33,951 (F) 50–79 y, 7 years | 400 IU/day   | 1000 mg/day  | Double-blind RCT                           | Nonsignificant effects on BMI, fat mass or WC                                                                                                                                                    |
| Nagpal et al. [106] | 100 (M) 35 y or older, 6 weeks | 360,000 IU/fortnightly | -            | Double-blind RCT                           | Participants with IFG: treatment group had a lower rise in fasting glucose compared with those on placebo and a lower increase in HOMA-IR                                                                 |
| Sneve et al. [107] | 445 (F, M) 21–70 y, 12 months | 20,000 IU/twice a week | 500 mg/day | Double-blind RCT                           | These differences were not present in normal fasting glucose subjects                                                                                                                                |
| Zitterman et al. [105] | 200 (F, M) 18–70 y, 12 months | 3320 IU/day   | -            | Double-blind RCT                           | There were no differences in C-reactive protein or IL-6 between groups                                                                                                                               |
| Zhou et al. [103] | 870 (F) 55 y or older, 4 years | 1100 IU/day  | 1400–1500 mg/day | Double-blind RCT                           | No significant results of dietary treatment on HR for incident diabetes                                                                                                                             |
| Rosenblum et al. [101] | 171 (F, M) 18–65 y, 16 weeks | 300 IU/day   | 1050 mg/day  | Double-blind RCT                           | Weight loss was not affected significantly                                                                                                                                                    |
| Forsythe et al. [102] | 212 (F, M) 20–40; >64 y, 22 weeks | 600 IU/day   | -            | Double-blind RCT                           | More pronounced decrease occurred in treatment group than in the placebo group in PTH, triglycerides, and the inflammation marker TNF-α. Vitamin D increased LDL                                             |
|                |                        |              |              | RCT                                         | The calcium intervention groups gained less trunk fat and maintained more trunk lean mass when compared to the placebo group, without difference with adding vitamin D                                         |
|                |                        |              |              | Oral vit D + oral Ca++                     | No significant difference was observed for BMI between groups                                                                                                                                         |
|                |                        |              |              | Placebo                                     | Treatment group increase decrease significantly more the % of visceral adipose tissue (−13 ± 16 vs. −5 ± 19)                                                                                     |
|                |                        |              |              | Oral vit D                                  | BMI in older adults was negatively associated with the change in 25(OH)D following supplementation. No such associations were apparent in younger adults                                                           |

RCT: randomized controlled trial; HR: hazard ratio; IFG: impaired fasting glucose; WRP: weight reduction program; BMI: body mass index; WC: waist circumference.
The results of two studies showed no positive effects of vitamin D on obesity markers [106,107]. These studies used higher doses than those previously cited (2857 to 24,000 IU/day) and one of them [106] lasted only 6 weeks. Three months of vitamin D supplementation are needed to achieve adequate serum levels for those deficient [13,107]. It is possible that very high doses of vitamin D may impair its function, as was evidenced in studies that evaluated the effect of high doses of vitamin D on bone health, and a minimum duration of 3 months is required in studies that assess the effects of supplementation of this vitamin.

Despite the short duration of the study conducted by Nagpal et al. [106], it was possible to observe an improvement in postprandial insulin sensitivity with the use of 360,000 IU of vitamin D every two weeks (24,000 IU/day) for six weeks. Pittas et al. [84] observed that the use of moderate doses of this vitamin (700 IU/day) associated with calcium over 3 years promoted a lower increase in fasting glucose and the HOMA-IR index in older adults with altered fasting glucose, but not in those with normal fasting glucose. Vitamin D can thus improve glycemic control and decrease insulin resistance, especially in subjects with altered glucose, contributing to the prevention and treatment of T2DM. Nevertheless, a robust study conducted with 33,951 postmenopausal women [85] showed no protective effect of a dietary intake of 400 IU of vitamin D combined with 1000 mg of calcium in reducing the incidence of T2DM. The effects of different doses of Vitamin D, alone or in conjunction with calcium on the prevention and/or treatment of T2DM need to be elucidated.

6. Conclusions

Vitamin D has hormonal action on various tissues and organs and its functions have been intensively reassessed with the discovery of the vitamin D receptor in most cells of the human body. The effects of vitamin D on bone metabolism are the best established. Besides increasing the circulating levels of calcium and phosphorus and promoting the mineralization process, this vitamin controls osteoblast and osteoclast function/differentiation and promotes bone formation, possibly by mechanisms to combat parathyroid hormone hypersecretion. These effects are evident in most intervention studies, especially in those that have evaluated the effects of vitamin doses equal to or higher than 800 IU/day on bone mineral density and that include calcium. Individual characteristics influence the response to the vitamin, such as the presence of obesity, which can increase the vitamin D demand, and the type of polymorphism of the vitamin D receptor. However, the use of megadoses of vitamin D with large intervals between administrations should be avoided, as they impair bone health.

Vitamin D seems to contribute to obesity and type 2 diabetes control by several mechanisms, including the regulation of adipogenesis during adipocyte differentiation, the stimulation of insulin synthesis and protection of pancreatic β-cells, and reducing insulin resistance in muscles. This vitamin may also contribute indirectly to combat these diseases through its action on bone tissue and the immune system, which liberates mediators that influence body weight gain and the inflammatory state. Nevertheless, recent studies question the cause and effect relationship between serum vitamin D levels and obesity. To date, there is not enough scientific evidence to support the use of vitamin D as a way to prevent and/or treat obesity and diabetes. Performing double-blind large-scale controlled trials to better establish the effects of vitamin D in chronic diseases of non-bone origin are required.
Acknowledgments

The authors thank Nature Publishing Group for kindly providing Figure 1 for adaptation and inclusion in this article and FAPEMIG, CAPES, and CNPq for the financial support.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Lips, P.; Schoor, N.M.V. The effect of vitamin D on bone and osteoporosis. *Best Pract. Res. Clin. Endocrinol. Metab.* **2011**, *25*, 585–591.
2. Rosen, C.J.; Adams, J.S.; Bikle, D.D.; Black, D.M.; Demay, M.B.; Manson, J.E.M.; Murad, H.; Kovacs, C.S. The nonskeletal effects of vitamin D: An endocrine society scientific statement. *Endocr. Rev.* **2012**, *33*, 456–492.
3. Gomez-Ambrosi, J.; Rodriguez, A.; Catalan, V.; Fruhbeck, G. The bone-adipose axis in obesity and weight loss. *Obes. Surg.* **2008**, *18*, 1134–1143.
4. Migliaccio, S.; Greco, E.A.; Fornari, R.; Donini, L.M.; Lenzi, A. Is obesity in women protective against osteoporosis? *Diabetes Metab. Syndr. Obes.* **2011**, *4*, 273–282.
5. Ross, A.C.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; Kovacs, C.S.; *et al*. Institute of medicine (US) committee to review dietary reference intakes for vitamin D and calcium. In *Dietary Reference Intakes for Calcium and Vitamin D*; Ross, A.C., Taylor, C.L., Yaktine, A.L., Valle, H.B.D., Eds.; National Academies Press (US): Washington, DC, USA, 2011.
6. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *J. Clin. Endocrinol. Metab.* **2011**, *96*, 1911–1930.
7. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 1153–1158.
8. Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.C.; Jurutka, P.W. Molecular mechanisms of vitamin D action. *Calcif. Tissue Int.* **2013**, *92*, 77–98.
9. Ashwell, M.; Stone, E.M.; Stolte, H.; Cashman, K.D.; Macdonald, H.; Lanham-New, S.; Hiom, S.; Webb, A.; Frase, D. UK food standards agency workshop report: An investigation of the relative contributions of diet and sunlight to vitamin D status. *Br. J. Nutr.* **2010**, *104*, 603–611.
10. Tsiaras, W.G.; Weinstoc, M.A. Factors influencing vitamin D status. *Acta Derm. Venereol.* **2011**, *91*, 115–124.
11. Bens, G. Sunscreens. *Adv. Exp. Med. Biol.* **2008**, *624*, 137–161.
12. Blum, M.; Dolnikowski, G.; Seyoum, E.; Harris, S.S.; Booth, S.L.; Peterson, J.; Saltzman, E.; Dawson-Hughes, B. Vitamin D(3) in fat tissue. *Endocrine* **2008**, *33*, 90–94.
13. Hanley, D.A.; Cranney, A.; Jones, G.; Whiting, S.J.; Leslie, W.D.; Cole, D.E.C.; Atkinson, S.A.; Josse, R.G.; Feldman, S.; Kline, G.A.; et al. Vitamin D in adult health and disease: A review and guideline statement from Osteoporosis Canada. *Can. Med. Assoc. J.* 2010, 182, 610–618.

14. Holick, M.F. The role of vitamin D for bone health and fracture prevention. *Curr. Osteoporos. Rep.* 2006, 4, 96–102.

15. Souberbielle, J.C.; Body, J.J.; Lappe, J.M.; Plebani, M.; Shoenfeld, Y.; Wang, T.J.; Bischoff-Ferrari, H.A.; Cavalier, E.; Ebeling, P.R.; Fardellone, P.; et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. *Autoimmun. Rev.* 2010, 9, 709–715.

16. Bischoff-Ferrari, H.A.; Shao, A. Dawson-Hughes, B.; Hathcock, J.; Giovannucci, E.; Willett, W.C. Benefit-Risk assessment of vitamin D supplementation. *Osteoporos. Int.* 2010, 21, 1121–1132.

17. Cunningham, J.; Locatelli, F.; Rodriguez, M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. *Clin. J. Am. Soc. Nephrol.* 2011, 6, 913–921.

18. Lamprecht, A.S.; Lipkin, M. Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. *Nat. Rev. Cancer* 2003, 3, 601–614.

19. Peacock, M. Calcium metabolism in health and disease. *Clin. J. Am. Soc. Nephrol.* 2010, 5, 23–30.

20. Lips, P. Vitamin D physiology. *Prog. Biophys. Mol. Biol.* 2006, 92, 4–8.

21. Yasuda, H.; Higashio, K.; Suda, T. Vitamin D and osteoclastogenesis. In *Vitamin D*; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: San Diego, CA, USA, 2005; Volume 2, pp. 665–685.

22. Lisse, T.S.; Chun, R.F.; Rieger, S.; Adams, J.S.; Hewison, M. Vitamin D activation of functionally distinct regulatory miRNAs in primary human osteoblasts. *J. Bone Miner. Res.* 2013, 28, 1478–1488.

23. Kogawa, M.; Anderson, P.H.; Findlaya, D.M.; Morris, H.A.; Atkins, G.J. The metabolism of 25-(OH) vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. *J. Steroid Biochem. Mol. Biol.* 2010, 121, 277–280.

24. Diamond, T.; Wong, Y.K.; Golombick, T. Effect of oral cholecalciferol 2000 vs. 5000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency. *Osteoporos. Int.* 2013, 24, 1101–1105.

25. Martin, T.J.; Sims, N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. *Trends Mol. Med.* 2005, 11, 76–81.

26. Zhu, K.; Devine, A.; Dick, I.M.; Wilson, S.G.; Prince, R.L. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: A five-year randomized controlled trial. *J. Clin. Endocrinol. Metab.* 2008, 93, 743–749.

27. Bischoff-Ferrari, H.A.; Dietrich, T.; Orav, E.J.; Dawson-Hughes, B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. *Am. J. Med.* 2004, 116, 634–639.

28. Kuchuk, N.O.; Pluimj, S.M.; van Schoor, N.M.; Looman, C.W.; Smit, J.H.; Lips, P. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. *J. Clin. Endocrinol. Metab.* 2009, 94, 1244–1250.
29. Kuchuk, N.O.; van Schoor, N.M.; Pluijm, S.M.; Chines, A.; Lips, P. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: Global perspective. *J. Bone Miner. Res.* 2009, 24, 693–701.

30. Van Schoor, N.M.; Visser, M.; Pluijm, S.M.; Kuchuk, N.; Smit, J.H.; Lips, P. Vitamin D deficiency as a risk factor for osteoporotic fractures. *Bone* 2008, 42, 260–266.

31. Larrosa, M.; Gomez, A.; Casado, E.; Moreno, M.; Vázquez, I.; Orellana, C.; Berlanga, E.; Ramon, J.; Gratacos, J. Hypovitaminosis D as a risk factor of hip fracture severity. *Osteoporus Int.* 2012, 23, 607–661.

32. Holick, M.F.; Siris, E.S.; Binkley, N.; Beard, M.K.; Khan, A.; Katzer, J.T.; Petruschke, R.A.; Chen, E.; de Papp, A.E. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. *J. Clin. Endocrinol. Metab.* 2005, 8, 3215–3224.

33. Harwood, R.H.; Sahota, O.; Gaynor, K.; Masud, T.; Hosking, D.J. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) study. *Age Ageing* 2004, 33, 45–51.

34. Jackson, R.D.; LaCroix, A.Z.; Gass, M.; Wallace, R.B.; Robbins, J.; Lewis, C.E.; Bassford, T.; Beresford, S.A.A.; Black, H.R.; Blanchette, P.; et al. Calcium plus vitamin D supplementation and the risk of fractures. *N. Engl. J. Med.* 2006, 354, 669–683.

35. Karkkainen, M.; Tuppurainen, M.; Salovaara, K.; Sandini, L.; Rikkonen, T.; Sirola, J.; Honkanen, R.; Jurvelin, J.; Alhava, E.; Kröger, H. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65–71 years: A 3-year randomized population-based trial (OSTPRE-FPS). *Osteoporus Int.* 2010, 21, 2047–2055.

36. Moschonis, G.; Katsaroli, I.; Lyritis, G.P.; Manios, Y. The effects of a 30-month dietary intervention on bone mineral density: The postmenopausal health study. *Br. J. Nutr.* 2010, 104, 100–107.

37. Jorde, R.; Sneve, M.; Torjesen, P.A.; Figenschau, Y.; Hansen, J-B.; Grimnes, G. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. *Nutr. J.* 2010, 9, 1, doi:10.1186/1475-2891-9-1.

38. Islam, M.Z.; Shamim, A.; Viljakainen, H.T.; Akhtaruzzaman, M.; Jehan, A.H.; Khan, H.U.; Al-Arif, F.A.; Lamberg-Allardt, C. Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: A double-blinded, randomised, placebo-controlled 1-year intervention. *Br. J. Nutr.* 2010, 104, 241–247.

39. Rastelli, A.L.; Taylor, M.E.; Gao, F.; Armamento-Villareal, R.; Jamalabadi-Majidi, S.; Napoli, N.; Ellis, M.J. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): A phase II, double-blind, placebo-controlled, randomized trial. *Breast Cancer Res. Treat.* 2011, 129, 107–116.

40. Steffensen, L.H.; Jorgensen, L.; Straume, B.; Mellgren, S.I.; Kampman, M.T. Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. *J. Neurol.* 2011, 258, 1624–1631.
41. Verschueren, S.M.P.; Bogaerts, A.; Delecluse, C.; Claessens, A.L.; Haentjens, P.; Vanderschueren, D.; Boonen, S. The effects of whole-body vibration training and vitamin D supplementation on muscle strength, muscle mass, and bone density in institutionalized elderly women: A 6-month randomized, controlled trial. J. Bone Miner. Res. 2011, 26, 42–49.

42. Grimnes, G.; Joakimsen, R.; Figenschau, Y.; Torjesen, P.A.; Almas, B.; Jorde, R. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass-a randomized controlled 1-year trial. Osteoporos. Int. 2012, 23, 201–211.

43. Nieves, J.; Cosman, F.; Grubert, E.; Ambrose, B.; Ralston, S.; Lindsay, R. Skeletal effects of vitamin D supplementation in postmenopausal black women. Calcif. Tissue Int. 2012, 91, 316–324.

44. Macdonald, H.M.; Wood, A.D.; Aucott, L.S.; Black, A.J.; Fraser, W.D.; Mavroeidi, A.; Reid, D.M.; Secombes, K.R.; Simpson, W.G.; Thies, F. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: A 1 year double-blind RCT in postmenopausal women. J. Bone Miner. Res. 2013, 28, 2202–2213.

45. Wamberg, L.; Pedersen, S.B.; Richelsen, B.; Rejnmark, L. The effect of high-dose vitamin D supplementation on calcitropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin D: Results from a randomized controlled study. Calcif. Tissue Int. 2013, 93, 69–77.

46. Lenchik, L.; Kiebzak, G.M.; Blunt, B.A. What is the role of serial bone mineral density measurements in patient management? J. Clin. Densitom. 2002, 5, 29–38.

47. Trivedi, D.; Doll, R.; Khaw, K. Effect of four monthly oral vitamin D supplementation on fractures and mortality in men and women living in the community: Randomized double blind controlled trial. BMJ 2003, 326, 469–475.

48. Larsen, E.R.; Mosekilde, L.; Foldspang, A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: A pragmatic population-based 3-year intervention study. J. Bone Miner. Res. 2004, 19, 370–378.

49. Grant, A.M.; Avenell, A.; Campbell, M.K.; McDonald, A.M.; MacLennan, G.S.; McPherson, G.C.; Anderson, F.H.; Cooper, C.; Francis, R.M.; Donaldson, C.; et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised evaluation of Calcium or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet 2005, 365, 1621–1628.

50. Porthouse, J.; Cockayne, S.; King, C.; Saxon, L.; Steele, E.; Aspray, T.; Baverstock, M.; Birks, Y.; Dumville, J.; Francis, R.; et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005, 330, 1003.

51. Flicker, L.; MacInnis, R.J.; Stein, M.S.; Scherer, S.C.; Mead, K.E.; Nowson, C.A.; Thomas, J.; Lowndes, C.; Hopper, J.L.; Wark, J.D. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J. Am. Geriatr. Soc. 2005, 53, 1881–1888.

52. Lyons, R.A.; Johansen, A.; Brophy, S.; Newcombe, R.G.; Phillips, C.J.; Lervy, B.; Evans, R.; Wareham, K.; Stone, M.D. Preventing fractures among older people living in institutional care: A pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos. Int. 2007, 18, 811–818.
53. Smith, H.; Anderson, F.; Raphael, H.; Maslin, P.; Crozier, S.; Cooper, C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women: a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)* 2007, 46, 1852–1857.

54. Pfeifer, M.; Begerow, B.; Minne, H.W.; Suppan, K.; Fahrleitner-Pammer, A.; Dobnig, H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos. Int.* 2009, 20, 315–322.

55. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. *JAMA* 2010, 303, 1815–1822.

56. Salovaara, K.; Tuppurainen, M.; Karkkainen, M.; Rikkonen, T.; Sandini, L.; Sirola, J.; Honkanen, R.; Alhava, E.; Kröger, H. Effect of vitamin D(3) and calcium on fracture risk in 65-to 71-year-old women: A population-based 3-year randomized, controlled trial: The OSTPRE-FPS. *J. Bone Miner. Res.* 2010, 25, 1487–1495.

57. Bakhtiyarova, S.; Lesnyak, O.; Kyznesova, N.; Blankenstein, M.A.; Lips, P. Vitamin D status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. *Osteoporos. Int.* 2006, 17, 441–446.

58. Bischoff-Ferrari, H.A.; Willett, W.C.; Orav, E.J.; Lips, P.; Meunier, P.J.; Flicker, L.; Wark, J.; Jackson, R.D.; Cauley, J.A.; Meyer, H.E.; et al. A pooled analysis of vitamin D dose requirements for fracture prevention. *N. Engl. J. Med.* 2012, 367, 40–49.

59. Lamendola, C.A.; Ariel, D.; Feldman, D.; Reaven, G.M. Relations between obesity, insulin resistance, and 25-hydroxyvitamin D. *Am. J. Clin. Nutr.* 2012, 95, 1055–1059.

60. Wolden-Kirk, H.; Overbergh, L.; Christesen, H.T.; Brusgaard, K.; Mathieu, C. Vitamin D and diabetes: Its importance for beta cell and immune function. *Mol. Cell. Endocrinol.* 2011, 347, 106–120.
69. Maestro, B.; Molero, S.; Bajo, S.; Dávila, N.; Calle, C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D3. *Cell Biochem. Funct.* **2002**, *20*, 227–232.

70. Dunlop, T.W.; Väisänen, S.; Frank, C.; Molnár, F.; Sinkkonen, L.; Carlberg, C.; Karn, J. The human peroxisome proliferator-activated receptor δ gene is a primary target of 1α, 25-dihydroxyvitamin D3 and its nuclear receptor. *J. Mol. Biol.* **2005**, *349*, 248–260.

71. Maestro, B.; Campion, J.; Davila, N.; Calle, C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. *Endocr. J.* **2000**, *47*, 383–391.

72. Holick, M.F. Vitamin D deficiency. *N. Engl. J. Med.* **2007**, *357*, 266–281.

73. Vimaleswaran, K.S.; Berry, D.J.; Lu, C.; Tikkanen, E.; Pilz, S.; Hiraki, L.T.; Cooper, J.D.; Dastani, Z.; Li, R.; Houston, D.K.; *et al*. Causal relationship between obesity and vitamin D status: Bi-directional mendelian randomization analysis of multiple cohorts. *PLoS Med.* **2013**, *10*, 1–13.

74. Lee, N.K.; Sowa, H.; Hinoi, E.; Ferron, M.; Ahn, J.D.; Confavreux, C.; Dacquin, R.; Mee, P.J.; McKee, M.D.; Jung, D.Y.; *et al*. Endocrine regulation of energy metabolism by the skeleton. *Cell* **2007**, *130*, 456–469.

75. Gómez-Ambrosi, J.; Catalán, V.; Ramírez, B.; Rodríguez, A.; Colina, I.; Silva, C.; Rotellar, F.; Mugueta, C.; Gil, M.J.; Cienfuegos, J.A.; *et al*. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. *J. Clin. Endocrinol. Metab.* **2007**, *92*, 3719–3727.

76. Nomiyama, T.; Perez-Tilve, D.; Ogawa, D.; Gizard, F.; Zhao, Y.; Heywood, E.B.; Jones, K.L.; Kawamori, R.; Cassis, L.A.; Tschöp, M.H.; *et al*. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. *J. Clin. Investig.* **2007**, *117*, 2877–2888.

77. Fukumoto, S.; Martin, T.J. Bone as an endocrine organ. *Trends Endocrin. Met.* **2009**, *20*, 230–236.

78. Almerighi, C.; Sinistro, A.; Cavazza, A.; Ciaprini, C.; Rocchi, G.; Bergamini, A. 1α,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. *Cytokine* **2009**, *45*, 190–197.

79. Eftekharian, M.M.; Zarnani, A.H.; Moazzeni, S.M. *In vivo* effects of calcitriol on phenotypic and functional properties of dendritic cells. *Iran J. Immunol.* **2010**, *7*, 74–82.

80. Jeffery, L.E.; Burke, F.; Mura, M.; Zheng, Y.; Qureshi, O.S.; Hewison, M.; Walker, L.S.; Lammas, D.A.; Raza, K.; Sansom, D.M. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. *J. Immunol.* **2009**, *183*, 5458–5467.

81. Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J. Immunol.* **2007**, *179*, 1634–1647.

82. Baeke, F.; Takiishi, T.; Korh, H.; Gyselms, C.; Mathieu, C. Vitamin D: Modulator of the immune system. *Curr. Opin. Pharmacol.* **2010**, *10*, 482–496.

83. Ducloux, R.; Nobécourt, E.; Chevallier, J.M.; Ducloux, H.; Elian, N.; Altman, J.J. Vitamin D deficiency before bariatric surgery: Should supplement intake be routinely prescribed? *Obes. Surg.* **2011**, *21*, 556–560.
84. Pittas, A.G.; Lau, J.; Hu, F.B.; Dawson-Hughes, B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* 2007, 92, 2017–2029.

85. De Boer, I.H.; Tinker, L.F.; Connelly, S.; Curb, J.D.; Howard, B.V.; Kestenbaum, B.; Larson, J.C.; Manson, J.E.; Margolis, K.L.; Siscovick, D.S.; *et al.* Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health Initiative. *Diabetes Care* 2008, 31, 701–707.

86. Aloia, J.F. African Americans, 25-hydroxyvitamin D, and osteoporosis: A paradox. *Am. J. Clin. Nutr.* 2008, 88, 545–550.

87. Devaraj, S.; Jialal, G.; Cook, T.; Siegel, D.; Jialal, I. Low vitamin D levels in Northern American adults with the metabolic syndrome. *Horm. Metab. Res.* 2011, 43, 72–74.

88. Elsammak, M.Y.; Al-Wosaibi, A.A.; Al-Howeish, A.; Alsaeed, J. Vitamin D deficiency in Saudi Arabs. *Horm. Metab. Res.* 2010, 42, 364–368.

89. Binkley, N.; Novotny, R.; Krueger, D.; Kawahara, T.; Daida, Y.G.; Lensmeyer, G.; Hollis, B.W.; Drezner, M.K. Low vitamin D status despite abundant sun exposure. *J. Clin. Endocrinol. Metab.* 2007, 92, 2130–2135.

90. Snijder, M.B.; van Dam, R.M.; Visser, M.; Deeg, D.J.; Dekker, J.M.; Bouter, L.M.; Seidell, J.C.; Lips, P. Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. *J. Clin. Endocrinol. Metab.* 2005, 90, 4119–4123.

91. Shankar, A.; Sabanayagam, C.; Kalidindi, S. Serum 25-hydroxyvitamin D levels and prediabetes among subjects free of diabetes. *Diabetes Care* 2011, 34, 1114–1119.

92. Pittas, A.G.; Chung, M.; Trikalinos, T.; Mitri, J.; Brendel, M.; Patel, K.; Lichtenstein, A.H.; Lau, J.; Balk, E.M. Systematic review: Vitamin D and cardiometabolic outcomes. *Ann. Intern. Med.* 2010, 152, 307–314.

93. Jorde, R.; Sneve, M.; Emaus, N.; Figenschau, Y.; Grimnes, G. Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: The Tromso study. *Eur. J. Nutr.* 2010, 49, 401–407.

94. Lagunova, Z.; Porojnicu, A.C.; Lindberg, F.A.; Aksnes, L.; Moan, J. Vitamin D status in Norwegian children and adolescents with excess body weight. *Pediatr. Diabetes* 2011, 12, 120–126.

95. Nunlee-Bland, G.; Gambhir, K.; Abrams, C.; Abdul, M.; Vahedi, M.; Odonkor, W. Vitamin D deficiency and insulin resistance in obese African-American adolescents. *J. Pediatr. Endocrinol. Metab.* 2011, 24, 29–33.

96. Rajakumar, K.; de las Heras, J.; Chen, T.C.; Lee, S.; Holick, M.F.; Arslanian, S.A. Vitamin D status, adiposity, and lipids in black American and Caucasian children. *J. Clin. Endocrinol. Metab.* 2011, 96, 1560–1567.

97. Muscogiuri, G.; Sorice, G.P.; Priorellata, A.; Pollicola, C.; della Casa, S.; Pontecorvi, A.; Giaccari, A. 25-hydroxyvitamin D concentration correlates with insulin sensitivity and BMI in obesity. *Obesity* 2010, 18, 1906–1910.
98. Gulseth, H.L.; Gjelstad, I.M.; Tierney, A.C.; Lovegrove, J.A.; Defoort, C.; Blaak, E.E.; Lopez-Miranda, J.; Kiec-Wilk, B.; Risérus, U.; Roche, H.M.; *et al*. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. *Diabetes Care* **2010**, *33*, 923–925.

99. Del Gobbo, L.C.; Song, Y.; Dannenbaum, D.A.; Dewailly, E.; Egeland, G.M. Serum 25-hydroxyvitamin D is not associated with insulin resistance or beta cell function in Canadian Cree. *J. Nutr.* **2011**, *141*, 290–295.

100. Chacko, S.A.; Song, Y.; Manson, J.E.; van Horn, L.; Eaton, C.; Martin, L.W.; McTiernan, A.; Curb, J.D.; Wylie-Rosett, J.; Phillips, L.S.; *et al*. Serum 25-hydroxyvitamin D concentrations in relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women. *Am. J. Clin. Nutr.* **2011**, *94*, 209–217.

101. Rosenblum, J.L.; Castro, V.M.; Moore, C.E.; Kaplan, L.M. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. *Am. J. Clin. Nutr.* **2012**, *95*, 101–108.

102. Forsythe, L.K.; Livingstone, M.B.; Barnes, M.S.; Horigan, G.; McSorley, E.M.; Bonham, M.P.; Magee, P.J.; Hill, T.R.; Lucey, A.J.; Cashman, K.D.; *et al*. Effect of adiposity on vitamin D status and the 25-hydroxycholecalciferol response to supplementation in healthy young and older Irish adults. *Br. J. Nutr.* **2012**, *107*, 126–134.

103. Zhou, J.; Zhao, L.J.; Watson, P.; Zhang, Q.; Lappe, J.M. The effect of calcium and vitamin D supplementation on obesity in postmenopausal women: secondary analysis for a large-scale, placebo controlled, double-blind, 4-year longitudinal clinical trial. *Nutr. Metab.* **2010**, *23*, 7–62.

104. Major, G.C.; Alarie, F.; Doré, J.; Phouttama, S.; Tremblay, A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. *Am. J. Clin. Nutr.* **2007**, *85*, 54–59.

105. Zittermann, A.; Frisch, S.; Berthold, H.K.; Göttling, C.; Kuhn, J.; Kleesiek, K.; Stehle, P.; Koertke, H.; Koerfer, R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am. J. Clin. Nutr.* **2009**, *89*, 1321–1327.

106. Nagpal, J.; Pande, J.N.; Bhartia, A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. *Diabetes Med.* **2009**, *26*, 19–27.

107. Sneve, M.; Figenschau, Y.; Jorde, R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. *Eur. J. Endocrinol.* **2008**, *159*, 675–684.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).